XLF-III-43

inhibits advanced glycation end products; structure in first source

Networked: 1 relevant articles (0 outcomes, 1 trials/studies)

1.	Diabetic Nephropathies (Diabetic Nephropathy) 02/10/2010 - "The streptozotocin-induced diabetic rats were used to investigate the beneficial effects of XLF-III-43 treatment on diabetic nephropathy. " 02/10/2010 - "The purpose of this study was to examine the novel coumarin-aspirin compound XLF-III-43 in the inhibition of AGE formation in diabetic nephropathy. " 02/10/2010 - "XLF-III-43, a novel coumarin-aspirin compound, prevents diabetic nephropathy in rats via inhibiting advanced glycation end products."
2.	Hypertrophy 02/10/2010 - "Moreover, XLF-III-43 ameliorated kidney hypertrophy, mesangial expansion and glomerulosclerosis in diabetic rats relative to untreated model group. "
3.	Hyperglycemia 02/10/2010 - "These data support further development of XLF-III-43 for prevention of nephropathy via inhibition of AGE formation consequent to chronic hyperglycemia."

1.	Aspirin (Acetylsalicylic Acid)
2.	coumarin
3.	Advanced Glycosylation End Products
4.	Streptozocin (Streptozotocin)